Abstract
BackgroundJuvenile idiopathic arthritis (JIA) is one of the most common rheumatic diseases of childhood. Adalimumab (ADA) is approved for use in moderate to severe polyarticular JIA (pJIA) patients (pts) ≥4...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have